Lenalidomide-Associated ITP
نویسندگان
چکیده
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
منابع مشابه
Low Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant
Background: Lenalidomide, a synthetic immunomodulatory drug, has a wide range of features including anti-angiogenic and anti-proliferative properties. To date, researchers have shown that lenalidomide is capable of ameliorating the immune system factors and antitumor responses. Most researchers have reported that lenalidomide enhances the immune response in certain cancer patients through sever...
متن کاملA Study of Epidemiology and Therapeutic Response of Patients with Immune Thrombocytopenic Purpura
Background: Immune thrombocytopenic purpura (ITP) is a disease characterized by decrease of the peripheral blood platelet count. The disease presents in acute and chronic forms. Because of the importance and high prevalence of ITP, it was decided to study the therapeutic response of patients with ITP. Material and Methods: A cross-sectional study was conducted at Ghaem hospital, Mashhad, Ira...
متن کاملLenalidomide-associated hepatotoxicity--a case report and literature review.
BACKGROUND Lenalidomide is an immunomodulatory drug frequently used for treatment of patients with multiple myeloma and myelodysplastic syndromes. This report presents a rare case of lenalidomide-associated hepatotoxicity and reviews the available literature. CASE REPORT A 67-year-old male with multiple myeloma was hospitalized with nausea, vomiting and jaundice, while treated with a second t...
متن کاملClinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old
Abstract Background Immune thrombocytopenic purpura (ITP) is the most prevalent cause of thrombocytopenia in children. Despite the importance of ITP in children under 2- years old, only a few publications are available in the literature. ITP usually presents itself as isolated thrombocytopenia and mucocutaneous bleeding. Materials and Methods T...
متن کاملThrombosis Associated with Immunomodulatory Agents in Multiple Myeloma
Patients with multiple myeloma (MM) are increasingly at risk for thromboembolic events (TEEs), usually venous thromboembolism (VTE) [1]. The introduction of thalidomide and lenalidomide has clearly improved outcomes in MM patients but these immunomodulatory agents (IMiDs) are also associated with higher rates of TEEs [2]. The pathogenesis of thalidomide/lenalidomide-associated thrombosis is mul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2011 شماره
صفحات -
تاریخ انتشار 2011